PhytoMedical’s Anti-Cancer Compound Effective at Killing Brain Cancer Cells
PhytoMedical Technologies, Inc. has announced that research outcomes from ongoing in vitro studies of the Company’s sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.
Led by Dartmouth College researcher Dr. Gordon Gribble, researchers have determined that, one of several patented “bis-intercalator” anti-cancer compounds being developed by PhytoMedical has achieved a 50% or greater cancer cell kill rate at a minimum concentration in studies of the SF-295 strain of human glioblastoma (brain) cancer cells -- a significant outcome, given these brain cancer cells’ drug-resistant nature.
“The outstanding results of this human cancer cell study is an extremely important step towards finding a potential solution for treating glioblastoma, an often fatal form of cancer,” commented Greg Wujek, President, CEO of PhytoMedical Technologies, Inc.
“The demonstrated cytotoxic effects of this unique patented compound on such a resistant strain of cancer has given us the confidence to move forward in our research and improve upon the concept of bis-intercalation and the promise it holds for the control of cancer.”
In important in vitro experiments, researchers tested several variations of patented bis-intercalator compounds. These compounds have the capability to “intercalate” or insert their anti-cancer molecules inside DNA sites of specific cancer cells, thereby preventing the ability of the cancer cells to replicate and ultimately forcing their death.
“We are very happy,” says Alla Kan Director of Dartmouth’s Technology Transfer Office, “that we found a good partner to help us bring these powerful new drugs claimed in Dartmouth College issued patent #6,187,787 to the patient as this is an ultimate goal of our office, to utilize research taking place in our laboratories for the public good.”